PMID- 30944686
OWN - NLM
STAT- MEDLINE
DCOM- 20190514
LR  - 20220408
IS  - 1918-1523 (Electronic)
IS  - 1203-6765 (Print)
IS  - 1203-6765 (Linking)
VI  - 2019
DP  - 2019
TI  - Postoperative Analgesic Effects of Different Doses of Epidural Hydromorphone 
      Coadministered with Ropivacaine after Cesarean Section: A Randomized Controlled 
      Trial.
PG  - 9054538
LID - 10.1155/2019/9054538 [doi]
LID - 9054538
AB  - PURPOSE: Single dose of epidural hydromorphone has been introduced to serve as an 
      alternative method for postcesarean section analgesia. However, optimal dose of 
      epidural hydromorphone remains unknown. Hence, we evaluated and compared the 
      analgesic and adverse effects of postoperative different doses of epidural 
      hydromorphone coadministered with ropivacaine after cesarean section. METHODS: 
      Eighty term parturients with elective cesarean section under epidural anesthesia 
      were allocated into four groups. Epidural analgesia was administered with an 
      epidural bolus of either 0 mg (group H0), or 0.2 mg (group H1), or 0.4 mg (group 
      H2), or 0.6 mg (group H3) hydromorphone coadministered with ropivacaine. The 
      primary outcome was the visual analogue pain scores (VAPSs) and rescue opioid 
      consumption (PCIA with sulfentanil) in 24 hours. Adverse effects such as 
      respiratory depression, pruritus, nausea, and vomiting were recorded. RESULTS: 
      The VAPSs of group H1 at 2, 4, 6, 12 h and 24 h after surgery was similar to 
      group H0. The VAPSs of group H2 at 4 and 6 h postoperatively were significantly 
      decreased when compared to group H0. But, the VAPSs of group H2 at 2, 12, and 
      24 h postoperatively were similar to those of group H0. The VAPSs of group H3 at 
      4, 6, 12 h, and 24 h after surgery were significantly decreased when compared to 
      those of group H0. The total sulfentanil consumption in 24 hours was 90 +/- 26 mug 
      in group H0, 75 +/- 29 mug in group H1, 54 +/- 32 mug in group H2, and 15 +/- 16 mug in 
      group H0. Adverse effects were comparable in the four groups. CONCLUSIONS: 
      Epidural administration of 0.6 mg hydromorphone coadministered with ropivacaine 
      after cesarean section provided satisfactory pain relief with less sulfentanil 
      consumption. This trial is registered with ChiCTR-IPR-16010026.
FAU - Yang, Meijuan
AU  - Yang M
AD  - Department of Anesthesiology, Women's Hospital, School of Medicine, Zhejiang 
      University, No. 2 Xueshi Road, Hangzhou, Zhejiang 310006, China.
FAU - Wang, Luyang
AU  - Wang L
AD  - Department of Anesthesiology, Women's Hospital, School of Medicine, Zhejiang 
      University, No. 2 Xueshi Road, Hangzhou, Zhejiang 310006, China.
FAU - Chen, Hong
AU  - Chen H
AD  - Department of Anesthesiology, Women's Hospital, School of Medicine, Zhejiang 
      University, No. 2 Xueshi Road, Hangzhou, Zhejiang 310006, China.
FAU - Tang, Yuwen
AU  - Tang Y
AUID- ORCID: 0000-0001-8923-8784
AD  - Department of Anesthesiology, Women's Hospital, School of Medicine, Zhejiang 
      University, No. 2 Xueshi Road, Hangzhou, Zhejiang 310006, China.
FAU - Chen, Xinzhong
AU  - Chen X
AUID- ORCID: 0000-0001-9219-1681
AD  - Department of Anesthesiology, Women's Hospital, School of Medicine, Zhejiang 
      University, No. 2 Xueshi Road, Hangzhou, Zhejiang 310006, China.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
DEP - 20190303
PL  - United States
TA  - Pain Res Manag
JT  - Pain research & management
JID - 9612504
RN  - 0 (Analgesics)
RN  - 7IO5LYA57N (Ropivacaine)
RN  - Q812464R06 (Hydromorphone)
SB  - IM
MH  - Adult
MH  - Analgesia, Epidural/methods
MH  - Analgesics/administration & dosage
MH  - *Cesarean Section/adverse effects
MH  - Double-Blind Method
MH  - Female
MH  - Humans
MH  - Hydromorphone/*administration & dosage
MH  - Middle Aged
MH  - Pain, Postoperative/*drug therapy/etiology
MH  - Patient Satisfaction
MH  - Pregnancy
MH  - Ropivacaine/*administration & dosage
MH  - Treatment Outcome
MH  - Young Adult
PMC - PMC6421812
EDAT- 2019/04/05 06:00
MHDA- 2019/05/15 06:00
PMCR- 2019/03/03
CRDT- 2019/04/05 06:00
PHST- 2018/06/24 00:00 [received]
PHST- 2019/01/22 00:00 [accepted]
PHST- 2019/04/05 06:00 [entrez]
PHST- 2019/04/05 06:00 [pubmed]
PHST- 2019/05/15 06:00 [medline]
PHST- 2019/03/03 00:00 [pmc-release]
AID - 10.1155/2019/9054538 [doi]
PST - epublish
SO  - Pain Res Manag. 2019 Mar 3;2019:9054538. doi: 10.1155/2019/9054538. eCollection 
      2019.